

MATERNAL-FETAL EXCHANGE: PLACENTA AS EMISSARY

Hilary S. Gammill, MD
March 24, 2016



UNIVERSITY *of*
WASHINGTON




FRED HUTCH
CURES START HERE™

DISCLOSURES:


- Research funding from Faraday Pharmaceuticals (sulfide metabolism in preeclampsia)

PLACENTA AS BARRIER



From Williams classic OB text, 1907: “The foetal blood in the vessels of the chorionic villi at no time gains access to the maternal blood in the intervillous spaces...”

PLACENTA AS EMISSARY



Maternal-Fetal Exchange:

- DNA
- RNA
- Extracellular vesicles
- Cells

Nelson, Scientific American, 2008



Reproductive origins of disease:

- Mother (placental disorders and later life health)
- Offspring (and cord blood transplant)

Cells

DNA

RNA

Extracellular vesicles

Immediate reflection of obstetric condition:

- Fetal/placental genetics
 - Placental function
- Adverse pregnancy outcomes

CELLULAR MICROCHIMERISM


Bidirectional maternal-fetal transfer
Long-term persistence

Fetal

Maternal


| Patient | Clinical history | | | | Interval between sampling and most recent male |
|---------|--------------------|--------------|----------------|---------|--|
| | No. of pregnancies | Male infants | Female infants | Tab/Sab | |
| 1 | 4 | 3 | 1 | 0 | 1 year |
| 2 | 3 | 1 | 2 | 0 | 7 years |
| 3 | 2 | 2 | 0 | 0 | 2 years |
| 4 | 3 | 2 | 1 | 0 | 3 years |
| 5 | 10 | 6 | 3 | 1 | 27 years |
| 6 | 3 | 2 | 0 | 1 | 6 years |
| 7 | 4 | 2 | 1 | 1 | 10 months |
| 8 | 1 | 1 | 0 | 0 | 6 months |

Bianchi, PNAS, 1996



Maloney, JCI, 1999

MICROCHIMERISM: CELL AND TISSUE TYPES



| Organ | Presumed cell type | Maternal origin Mc | Fetal origin Mc |
|-------------|--|--------------------|-----------------|
| Brain | Neurons(murine) | | X |
| Lymph node | Hematopoietic cells | | X |
| Thyroid | Epithelial cells, thyrocytes | | X |
| Blood | T cells, B cells, monocytes/ macrophages, NK cells, granulocytes | X | X |
| Blood | Lymphoid progenitor cells | | X |
| Heart | Cardiac myocytes | X | X |
| Skin | Endothelial cells | | X |
| Skin | Keratinocytes | X | |
| Spleen | Hematopoietic cells | | X |
| Kidney | Renal tubular cells | X | |
| Pancreas | Islet beta cells | X | |
| Liver | Hepatocytes | X | X |
| Gallbladder | Epithelial cells | | X |
| Intestine | Epithelial cells | | X |
| Cervix | Epithelial cells | | X |



CELLULAR MICROCHIMERISM

Cells exchanged during pregnancy can lead to persistent microchimerism:

- Among healthy adults,
 - 78% had detectable fetal microchimerism
 - 39% had detectable maternal microchimerism



Maternal later-life health:
Autoimmune disease
Cardiovascular disease
Cancer



Fetal origins of
adult disease

Placental disorders:
Preeclampsia

*Naturally acquired cellular microchimerism may contribute
to **reproductive origins of disease***

FETAL CELLULAR MICROCHIMERISM IN NORMAL PREGNANCY

- Longitudinal study of normal pregnancies:
 - 7/35 (20%) of women had detectable fetal microchimerism in PBMC in at least one time point
 - Detection and concentration increased with gestational age and was highest around delivery
 - Fetal microchimerism was detectable in CD4+ and CD8+ cell subsets in ~10%


FETAL CELLULAR MICROCHIMERISM IN PREECLAMPSIA

- 17/53 (32%) samples positive in preeclampsia
- 6/57 (10.5%) samples positive in normotensive pregnancies
- $p=0.007$

Concentration of Cellular Fetal Microchimerism Among Subjects With Preeclampsia and Subjects With Normal Pregnancy

| Group | Detection Rate Ratio (95% CI; <i>P</i> Value) | |
|--|--|-----------------------------|
| | Unadjusted | Adjusted* |
| Normal pregnancy, n=47 subjects (57 samples) | ... | ... |
| Preeclampsia, n=46 subjects (53 samples) | 17.4 (2.7–110.4; $P=0.002$) | 15.8 (3.2–77.8; $P<0.001$) |

PREECLAMPSIA IS ASSOCIATED WITH LATER CARDIOVASCULAR DISEASE



Bellamy, BMJ, 2007; Fraser, Circulation, 2012;
McDonald, Am J Heart, 2008; Smith, Lancet, 2001

DIRECT RELATIONSHIP: FETAL CELLULAR MICROCHIMERISM AND CV DISEASE

- Danish cohort of women enrolled between ages 50-64 (secondary analysis, case cohort study of cancer)
- Male microchimerism studied at time of enrollment
- Subsequent development of disease considered

| Male microchimerism negative (n = 82) | Male microchimerism positive (n = 190) | Crude OR (95% CI) |
|--|---|----------------------|
| 74 (32.2) | 156 (67.8) | 1 (ref.) |
| 8 (19.1) | 34 (81.0) | 2.0 (0.9–4.6) |

PREECLAMPSIA IS INVERSELY ASSOCIATED WITH BREAST CANCER RISK

- Linkage between Norwegian Medical Birth Registry and Cancer Registry

| | Person-years | Cases of Breast cancer | RR (95% CI) |
|-------|--------------|------------------------|------------------|
| No PE | 10,450,371 | 5,194 | 1.0 |
| PE | 663,311 | 280 | 0.81 (0.71-0.91) |

- Unchanged by:
 - Length of gestation (term vs. preterm)
 - Offspring birthweight
 - Woman's age

DIRECT RELATIONSHIP: MICROCHIMERISM AND BREAST CANCER PROTECTION

| | | | |
|------------------------------------|--|-------------------------------|--------------------------|
| Cases | Blood - Stage 0-IV ¹ | Blood - Stage I-III | Cancer-free breast |
| Controls | Blood – healthy women | Blood – matched women | Mammoplasty reduction |
| Prevalence Case:Control | 14% : 43% | 26% : 56% | 26% : 63% |
| OR (95%-CI) | 0.23 (0.06-0.75) | 0.29 (0.11–0.83) | 0.17 (0.04–0.76) |
| p-value | 0.006 | 0.02 | 0.02 |
| Comments | <ul style="list-style-type: none"> • Unselected breast cancer patients • Some with Chemo | Pre-menopausal (age 21-45) | |

Gadi V. Cancer Res. 2007; 67:9035-8

Gadi V. PLoS One. 2008; 3:e1706


Gadi V. Breast Cancer Res Treat. 2010; 121:241-4

FETAL CELLULAR MICROCHIMERISM AND PROTECTION FROM BREAST CANCER

- Danish Diet, Cancer, and Health Cohort
 - Microchimerism **preceding** disease onset

| | Breast cancer (<i>n</i> = 89) | Cancer-free (<i>n</i> = 272) |
|--|--------------------------------|-------------------------------|
| Detection of microchimerism (<i>n</i> , column %) | | |
| No | 53 (59.6) | 82 (30.1) |
| Yes | 36 (40.4) | 190 (69.9) |
| Odds ratio (95% confidence interval (CI)) | | |
| Adjusted | 0.30 (0.17–0.52) | 1 (Ref.) |

OVERALL SURVIVAL: BOTH RISK AND PROTECTION



| Status | All-cause mortality | Cancer mortality | Cardiovascular mortality |
|-------------------------|---------------------|------------------|--------------------------|
| Microchimerism positive | 0.42 (0.17–1.03) | 0.24 (0.08–0.79) | 1.66 (0.18–15.48) |
| Microchimerism negative | 1 (ref.) | 1 (ref.) | 1 (ref.) |



Reproductive origins of disease:

- Mother (placental disorders and later life health)
- Offspring (and cord blood transplant)

Cells

DNA

RNA

Extracellular vesicles

Immediate reflection of obstetric condition:

- Fetal/placental genetics
 - Placental function
- Adverse pregnancy outcomes

COLLABORATIVE STUDIES: FETAL/ PLACENTAL GENETICS

- Rapid evolution of the field of noninvasive prenatal testing (NIPT)



COLLABORATIVE STUDIES: FETAL/ PLACENTAL GENETICS

■ Breadth

RESEARCH ARTICLE

GENOMICS

Noninvasive Whole-Genome Sequencing of a Human Fetus

Jacob O. Kitzman,^{1*} Matthew W. Snyder,¹ Mario Ventura,^{1,2} Alexandra P. Lewis,¹ Ruolan Qiu,¹ LaVone E. Simmons,³ Hilary S. Gammill,^{3,4} Craig E. Rubens,^{5,6} Donna A. Santillan,⁷ Jeffrey C. Murray,⁸ Holly K. Tabor,^{5,9} Michael J. Bamshad,^{1,5} Evan E. Eichler,^{1,10} Jay Shendure^{1*}

www.ScienceTranslationalMedicine.org 6 June 2012 Vol 4 Issue 137 137ra76

■ Refinement

BRIEF REPORT

Copy-Number Variation and False Positive Prenatal Aneuploidy Screening Results


Matthew W. Snyder, M.S., LaVone E. Simmons, M.D., Jacob O. Kitzman, Ph.D., Bradley P. Coe, Ph.D., Jessica M. Henson, B.S., Riza M. Daza, B.S., Evan E. Eichler, Ph.D., Jay Shendure, M.D., Ph.D., and Hilary S. Gammill, M.D.

N ENGL J MED 372;17 NEJM.ORG APRIL 23, 2015

FUTURE COLLABORATIVE STUDIES

- Several UW departments
- Human Placenta Project proposal, aiming to:
 - Isolate and evaluate placental-derived cells, subcellular particles, and cell-free nucleic acids to assess placental function
 - Normal pregnancy
 - Preeclampsia


PLACENTA AS EMISSARY



Maternal-Fetal Exchange:

- DNA
- RNA
- Extracellular vesicles
- Cells

Nelson, Scientific American, 2008



SYNCYTIAL TRANSFER

J. Anat. (1986), **147**, pp. 245–254




With 11 figures

Printed in Great Britain

Scanning electron microscopy of intervillous connections in the mature human placenta

G. J. BURTON

*Department of Anatomy, University of Cambridge,
Downing Street, Cambridge CB2 3DY*





SYNCYTIAL “SECRETION”

Review: Does size matter? Placental debris and the pathophysiology of pre-eclampsia

C.W.G. Redman, D.S. Tannetta, R.A. Dragovic, C. Gardiner, J.H. Southcombe, G.P. Collett, I.L. Sargent*

Nuffield Department of Obstetrics and Gynaecology, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK

Placenta 33, Supplement A, Trophoblast Research, Vol. 26 (2012) S48–S54




EXTRAVILLOUS CYTOTROPHOBLAST INVASION

Preeclampsia Is Associated with Widespread Apoptosis of Placental Cytotrophoblasts within the Uterine Wall

American Journal of Pathology, Vol. 155, No. 1, July 1999

Elaine DiFederico,* Olga Genbacev,[†] and Susan J. Fisher*^{†‡§}

From the Departments of Obstetrics, Gynecology, and Reproductive Sciences, Stomatology,[†] Pharmaceutical Chemistry,[‡] and Anatomy,[§] University of California San Francisco, San Francisco, California*



CONCLUSIONS

- Maternal-fetal transplacental exchange includes cells, subcellular fragments, and cell-free nucleic acids
- Long-term persistence of exchanged cells may influence post-reproductive health
- Placental-derived material may provide a window into pregnancy status
- Many questions remain regarding the mechanism and nature of transplacental exchange

ACKNOWLEDGEMENTS

J. Lee Nelson, MD
James Roberts, MD
V.K. Gadi, MD, PhD
Katherine A. Guthrie, PhD
Kim Ma, MD
Kristina Adams Waldorf, MD
Swati Shree, MD
Coline Gentil, MS
Sami Kanaan, PhD
Judy Allen, MPH
Alisa Clein
David Eschenbach, MD and the
UW Department of Ob/Gyn,
Division of MFM

Jay A. Shendure, MD, PhD
Matthew W. Snyder, PhD

NICHD WRHR HD01264
NICHD K08HD067221
Preeclampsia Foundation



QUESTIONS?